Advertisement

International Journal of Legal Medicine

, Volume 121, Issue 3, pp 169–174 | Cite as

Medicolegal aspects of tetrazepam metabolism

  • Marion Pavlic
  • Kathrin Libiseller
  • Petra Grubwieser
  • Heinrich Schubert
  • Walter Rabl
Original Article

Abstract

The benzodiazepine tetrazepam is primarily muscle relaxant with comparably lower central sedating effects and is therefore commonly prescribed for muscle spasms of different origins. To evaluate tetrazepam metabolism, a study was conducted with ten healthy volunteers. Blood and urine samples were regularly collected after the intake of 50 mg tetrazepam. Toxicological analyses revealed that tetrazepam is also metabolized to diazepam and further to nordazepam, which has not yet been reported. Tetrazepam and diazepam could be detected in urine samples at least 72 h after intake, the diazepam concentration being 33% (±14% SD), on average, of the tetrazepam concentration. On the basis of three case histories, the importance of the detection of these newly described metabolites is shown as necessary to prevent false accusations and potential negative legal consequences for examined persons.

Keywords

Tetrazepam Diazepam Nordazepam Forensic toxicology 

Notes

Acknowledgements

The authors would like to thank Dr. Herbert Oberacher for valuable discussions and Mrs. Elisabeth Unterdorfer and Mr. Karl-Heinz Pramstrahler for their technical support within the laboratory.

References

  1. 1.
    Keane PE, Simiand J, Morre M, Biziere K (1988) Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exp Ther 245:692–698PubMedGoogle Scholar
  2. 2.
    Keane PE, Bachy A, Morre M, Biziere K (1988) Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites. J Pharmacol Exp Ther 245:699–705PubMedGoogle Scholar
  3. 3.
    Milanov I (1992) Mechanisms of tetrazepam action on spasticity. Acta Neurol Belg 92:5–15PubMedGoogle Scholar
  4. 4.
    Lobisch M, Schaffler K, Wauschkuhn H, Nickel B (1996) Clinical pilot study of the myogenic effects of flupirtine in comparison to tetrazepam and placebo (in German). Arzneimittelforschung 46:293–298PubMedGoogle Scholar
  5. 5.
    Simiand J, Keane PE, Biziere K, Soubrie P (1989) Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn Ther 297:272–285PubMedGoogle Scholar
  6. 6.
    Perez-Guerrero C, Suarez J, Herrera MD, Marhuenda E (1997) Vasodilating effects of tetrazepam in isolated vascular smooth muscles: comparison with cromakalim and diltiazem. Pharmacol Res 36:237–242PubMedCrossRefGoogle Scholar
  7. 7.
    Pellkofer M, Paulig M (1989) Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities (in German). Med Klin (Munich) 84:5–8Google Scholar
  8. 8.
    Rote Liste (2005) Tetrazepam. Rote Liste Win 2005/II version 4.2 Rote Liste Service GmbHGoogle Scholar
  9. 9.
    Baumgartner MG, Cautreels W, Langenbahn H (1984) Biotransformation and pharmacokinetics of tetrazepam in man. Arzneimittelforschung 34:724–729PubMedGoogle Scholar
  10. 10.
    Dussy FE, Hamberg C, Briellmann TA (2005) Quantification of benzodiazepines in whole blood and serum. Int J Legal Med Oct 12:1–8Google Scholar
  11. 11.
    Maurer H, Pfleger K (1987) Identification and differentiation of benzodiazepines and their metabolites in urine by computerized gas chromatography–mass spectrometry. J Chromatogr 422:85–101PubMedCrossRefGoogle Scholar
  12. 12.
    Staak M, Sticht G, Saternus KS, Kaferstein H (1982) Pharmacokinetic studies following administration of tetrazepam in rhesus monkeys. Beitr Gerichtl Med 40:323–328PubMedGoogle Scholar
  13. 13.
    Bun H, Philip F, Berger Y, Necciari J, Al Mallah NR, Serradimign A, Cano JP (1987) Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteers. Arzneimittelforschung 37:199–202PubMedGoogle Scholar
  14. 14.
    Staak M, Sticht G, Kaferstein H, Norpoth T (1984) Pharmacokinetics and metabolite pattern of tetrazepam and chlordesmethyldiazepam. Beitr Gerichtl Med 42:75–79PubMedGoogle Scholar
  15. 15.
    Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447–474PubMedGoogle Scholar
  16. 16.
    Geister U, Gaupp M, Arnold P, Schaarschmidt D, Doser K (2000) Bioavailability investigation of two different oral formulations of tetrazepam. Arzneimittelforschung 50:328–332PubMedGoogle Scholar
  17. 17.
    Concheiro M, Villain M, Bouchet S, Ludes B, Lopez-Rivadulla M, Kintz P (2005) Windows of detection of tetrazepam in urine, oral fluid, beard, and hair, with a special focus on drug-facilitated crimes. Ther Drug Monit 27:565–570PubMedCrossRefGoogle Scholar
  18. 18.
    Musshoff F, Dettmeyer R, Madea B (1998) Death in the bathtub—rectal drug administration. Arch Kriminol 201:80–86PubMedGoogle Scholar
  19. 19.
    Boccardi G, Deleuze C, Gachon M, Palmisano G, Vergnaud JP (1992) Autoxidation of tetrazepam in tablets: prediction of degradation impurities from the oxidative behavior in solution. J Pharm Sci 81:183–185PubMedCrossRefGoogle Scholar
  20. 20.
    Hammad MA, Muller BW (1998) Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci 7:49–55PubMedCrossRefGoogle Scholar
  21. 21.
    Guengerich FP (1991) Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 266:10019–10022PubMedGoogle Scholar
  22. 22.
    Porter TD, Coon MJ (1991) Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 266:13469–13472PubMedGoogle Scholar
  23. 23.
    Schütz H (1989) Benzodiazepines II. A handbook, 1st edn. Springer, Berlin Heidelberg New York, p 32Google Scholar
  24. 24.
    He YA, Roussel F, Halpert JR (2003) Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 409:92–101PubMedCrossRefGoogle Scholar
  25. 25.
    Steentoft A, Worm K, Pedersen CB, Sprehn M, Mogensen T, Sorensen MB, Nielsen E (1996) Drugs in blood samples from unconscious drug addicts after the intake of an overdose. Int J Legal Med 108:248–251PubMedCrossRefGoogle Scholar
  26. 26.
    Kaa E, Teige B (1993) Drug-related deaths during the 1980s. A comparative study of drug addict deaths examined at the institutes of forensic medicine in Aarhus, Denmark and Oslo, Norway. Int J Legal Med 106:5–9PubMedCrossRefGoogle Scholar
  27. 27.
    Favretto D, Frison G, Maietti S, Ferrara SD (2006) LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor. Int J Legal Med (in press) DOI  10.1007/s00414-006-0078-x

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Marion Pavlic
    • 1
  • Kathrin Libiseller
    • 1
  • Petra Grubwieser
    • 1
  • Heinrich Schubert
    • 2
  • Walter Rabl
    • 1
  1. 1.Institute of Legal MedicineInnsbruck Medical UniversityInnsbruckAustria
  2. 2.Department of Plastic and Reconstructive SurgeryInnsbruck Medical UniversityInnsbruckAustria

Personalised recommendations